Kim Tae-min
Seoul National University Hospital|Hematology and Oncology
Seoul Jongno-gu
Last updated
The clinical work of Professor Kim Tae-min, who has expertise in brain tumors and lymphoma as well as experience in clinical trials, demonstrates a reliable track record.
Medical opinions · Patient reviews0
No reviews yet.
If you've been treated by Kim Tae-min, be the first to leave a review.
Planning to see Kim Tae-min?
Save this doctor and find them again anytime on My page.
Ask other patients
If reviews don't answer your questions, ask patients and caregivers who have been there.
Patient stories: Hematology and Oncology
MoreHospital information
- Hospitals
- Seoul National University Hospital
- Specialties
- More Hematology and Oncology doctors
- Address
- 101 Daehak-ro, Jongno-gu, Seoul
- University
- 서울대학교 의과대학
- Appointments
- 1588-5700Book by phone (1588-5700)
Education and career
Education
- 2008–2012 Doctor of Medicine, Graduate School of Medicine, Seoul National University
- 2003–2005 Master of Medicine, Graduate School of Medicine, Seoul National University
- 1996–2000 Department of Medicine, Seoul National University College of Medicine
Career
- Current: Professor, Seoul National University College of Medicine, Mar. 2025–present
- Current: Clinical Professor, Department of Internal Medicine, Seoul National University Hospital, 2018–present
- 2013–2018 Clinical Associate Professor, Department of Internal Medicine, Seoul National University Hospital
- 2009–2013 Clinical Assistant Professor, Department of Internal Medicine, Seoul National University Hospital
- 2008–2009 Clinical Fellow, Department of Internal Medicine, Seoul National University Hospital
- Title: Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
- Journal: Ann Oncol
- Publication date: 2024
- PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/39147364/
- Title: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
- Journal: Lancet Oncol
- Publication date: 2024
- PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/39089305/
- Title: Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
- Journal: Clin Cancer Res
- Publication date: 2024
- PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/39150541/
- Title: Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
- Journal: Eur J Cancer
- Publication date: 2024
- PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/38981315/
- Title: A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)
- Journal: Lung Cancer
- Publication date: 2024
- PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/38986212/
Academic societies
- 2017–present Korean Association for Lung Cancer
- 2016–present American Association for Cancer Research
- 2011–present American Society of Clinical Oncology
- 2011–present International Association for the Study of Lung Cancer
- 2007–present Korean Association for Clinical Oncology
- 2006–present Korean Cancer Association
- 2005–present Korean Association of Internal Medicine
FAQ
- What conditions does Kim Tae-min treat?
- Kim Tae-min (Hematology and Oncology, Seoul National University Hospital) treats conditions such as Lung cancer, Lymphoma.
- Where does Kim Tae-min see patients?
- In Hematology and Oncology at Seoul National University Hospital. The hospital address is 101 Daehak-ro, Jongno-gu, Seoul.
- What is Kim Tae-min's specialty?
- Specialty: Hematology and Oncology.
Is any information wrong?
Let us know about changes to hospital, specialty, career and so on, and we'll update it after checking.